Semaglutide
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 572
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Treatment group A: HRS9531 injection | n/r | n/r | n/r | n/r |
| Treatment group B: Semaglutide Injection | n/r | n/r | n/r | n/r |
Not shown
- Treatment group A: HRS9531 injection: endpoint not reported
- Treatment group B: Semaglutide Injection: endpoint not reported